Arrowhead Pharmaceuticals Hits New 52-Week High at $31.67

Arrowhead Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 31.67 on September 19, 2025. This achievement underscores the company's notable performance within the Pharmaceuticals & Biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 3,756 million.
Over the past year, Arrowhead Pharmaceuticals has demonstrated a robust performance, recording a 25.21% increase, significantly outperforming the S&P 500, which saw a gain of 16.64% during the same period. Despite its current loss-making status, indicated by a negative price-to-earnings ratio, the company continues to navigate the competitive landscape of its industry.

Key financial metrics reveal a debt-to-equity ratio of -0.56 and a return on equity of -30.51%, reflecting the company's financial structure and operational efficiency. Additionally, Arrowhead Pharmaceuticals maintains a price-to-book ratio of 7.19, indicating its valuation relative to its assets. As the company continues to evolve, this new high marks an important chapter in its ongoing journey within the market.